SAT-130 - Efficacy and Tolerability of Simeprevir and Daclatasvir for 12 or 24 Weeks in HCV Genotype 1b-Infected Treatment-Naïve Patients with Advanced Fibrosis or Compensated Cirrhosis

Autor: Hezode, C., Almasio, P., Bourgeois, S., Buggisch, P., Brown, A., Diago, M., Horsmans, Y., Serfaty, L., Szalay, F., Gaeta, G.B., Planas, R., Schlag, M., Lonjon-Domanec, I., Gilles, L., DeMasi, R., Zeuzem, S.
Zdroj: In Journal of Hepatology 2016 64(2) Supplement:S754-S754
Databáze: ScienceDirect
Externí odkaz: